Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Therapeutics

• Publication date

  2002-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0149-2918(02)80088-1PMID 12501883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.

  2001cited by this paper
• The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg?

  2001cited by this paper
• Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.

  2001cited by this paper
• Clinical failures: the tip of the iceberg?

  2001cited by this paper
• Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.

  2001cited by this paper
• Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

  2001cited by this paper
• Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections.

  2001cited by this paper
• Risk Assessment for Antimicrobial Agent‐Induced QTc Interval Prolongation and Torsades de Pointes

  2001cited by this paper
• Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp.

  2000cited by this paper
• A Comparative In Vitro Surveillance Study of Gemifloxacin Activities against 2,632 Recent Streptococcus pneumoniaeIsolates from across Europe, North America, and South America

  2000cited by this paper
• Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults

  2000cited by this paper
• In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.

  2000cited by this paper
• Levofloxacino oral frente a ceftriaxona y a amoxicilina/ácido clavulánico intravenosos en el tratamiento de la neumonía adquirida en la comunidad que requiere hospitalización

  2000cited by this paper
• How short can courses be in lower respiratory tract infections?

  2000cited by this paper
• [Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization].

  2000cited by this paper
• Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.

  2000cited by this paper
• Treatment of Community-Acquired Pneumonia

  2000cited by this paper
• Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.

  2000cited by this paper
• Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.

  2000cited by this paper
• Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

  1999cited by this paper
• Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.

  1999cited by this paper
• Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

  1999cited by this paper
• Fluoroquinolone toxicity profiles: a review focusing on newer agents.

  1999cited by this paper
• In Vitro Activities of Gemifloxacin (SB 265805, LB20304) against Recent Clinical Isolates of Chlamydia pneumoniae

  1999cited by this paper
• Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia.

  1999cited by this paper
• A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia.

  1999cited by this paper
• The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards.

  1998cited by this paper
• Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.

  1997cited by this paper
• A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

  1997cited by this paper
• A prediction rule to identify low-risk patients with community-acquired pneumonia.

  1997cited by this paper
• Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.

  1997cited by this paper
• Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.

  1996cited by this paper
• Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.

  1996cited by this paper
• Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.

  1996cited by this paper
• Pharmacoeconomic Benefit of Antibiotic Step-Down Therapy: Converting Patents from Intravenous Ceftriaxone to Oral Cefpodoxime Proxettl

  1995cited by this paper
• Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia.

  1995cited by this paper
• Sequential therapy in the hospital management of lower respiratory infections.

  1995cited by this paper
• Intravascular catheter associated sepsis: a common problem

  1994cited by this paper
• Intravascular catheter associated sepsis: a common problem. The Australian Study on Intravascular Catheter Associated Sepsis.

  1994cited by this paper
• Singapore Med J

  1993cited by this paper
• Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial.

  1991cited by this paper
• The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia.

  1991cited by this paper
• Infectious complications with respiratory pathogens despite ciprofloxacin therapy.

  1991cited by this paper
• Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia

  1983cited by this paper

• Unraveling Ceftriaxone Dosing: Free Drug Prediction, Threshold Optimization, and Model Validation

  2025cites this paper
• Oral versus parenteral antibiotic therapy in adult patients with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.

  2023cites this paper
• Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis

  2019influential citation
• Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis

  2019cites this paper
• Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia.

  2016cites this paper
• The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia

  2015cites this paper
• Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?

  2013cites this paper
• Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials.

  2012cites this paper
• Are Fluoroquinolones Superior Antibiotics for the Treatment of Community-Acquired Pneumonia?

  2012cites this paper
• Optimal Pharmacological Therapy for Community-Acquired Pneumonia

  2012cites this paper
• Guide to Selection of Fluoroquinolones in Patients with Lower Respiratory Tract Infections

  2012cites this paper
• Bacteraemic Pneumococcal Pneumonia

  2011cites this paper
• Emerging drugs for pneumococcal pneumonia

  2011cites this paper
• Fluoroquinolones in the management of community‐acquired pneumonia

  2010cites this paper
• Fluoroquinolones in the management of community-acquired pneumonia in primary care

  2010cites this paper
• Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia.

  2010cites this paper
• Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy

  2009cites this paper
• Microbiological and Pharmacological Principles of Recent Antibiotic Therapy

  2009cites this paper
• The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.

  2008cites this paper
• Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.

  2008cites this paper
• Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

  2008cites this paper
• Gemifloxacin for community-acquired pneumonia

  2008cites this paper
• Role of gemifloxacin in community-acquired pneumonia

  2008cites this paper
• Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials

  2008cites this paper
• Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.

  2008cites this paper
• Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin

  2007cites this paper
• Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock*

  2007cites this paper
• XVe Conférence de consensus en thérapeutique anti-infectieuse

  2007cites this paper
• Prise en charge des pneumonies communautaires aux urgences

  2007cites this paper
• Gestione delle polmoniti comunitarie in pronto soccorso

  2007cites this paper
• Optimizing therapy for community-acquired pneumonia with the goal of rapid resolution of illness.

  2006cites this paper
• Medication options for the treatment of CAP.

  2006cites this paper
• Highlights on the appropriate use of fluoroquinolones in respiratory tract infections.

  2006cites this paper
• Geminofloxacin for the management of community-acquired respiratory tract infections.

  2006cites this paper
• Gemifloxacin for the Management of Community-Acquired Respiratory Tract Infections

  2006cites this paper
• Pneumonies aiguës communautaires : analyse critique des essais cliniques

  2006cites this paper
• Oral antibiotics versus parenteral antibiotics for severe pneumonia in children

  2006cites this paper
• [Acute community-acquired pneumonia. A review of clinical trials].

  2006cites this paper
• Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia.

  2005cites this paper
• Short-Course Antimicrobial Therapy for Community-Acquired Pneumonia

  2005cites this paper
• The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.

  2005cites this paper
• Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

  2005cites this paper
• NOD2 in Crohn's disease--loss or gain of function mutations?

  2005cites this paper
• Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia

  2005cites this paper
• Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.

  2005cites this paper
• An Approach to Evaluating Drug‐Nutrient Interactions

  2005cites this paper
• Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae.

  2005cites this paper
• Editorial Commentary: Optimizing Therapy for Community‐Acquired Pneumonia with the Goal of Rapid Resolution of Illness

  2005cites this paper
• Gemifloxacin for the Treatment of Respiratory Tract Infections: In Vitro Susceptibility, Pharmacokinetics and Pharmacodynamics, Clinical Efficacy, and Safety

  2005cites this paper
• Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm

  2005cites this paper
• The newer fluoroquinolones.

  2004cites this paper
• Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.

  2004cites this paper
• Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.

  2004influential citation
• Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections

  2004cites this paper
• Oral antibiotics versus parenteral antibiotics for severe pneumonia in children.

  2004cites this paper
• Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections

  2004cites this paper
• Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.

  2004cites this paper
• New Insights in the Treatment by Levofloxacin

  2004cites this paper
• New insights in the treatment by levofloxacin.

  2004cites this paper
• Gemifloxacin: a new fluoroquinolone

  2004influential citation
• Treatment of Community-Acquired Respiratory Tract Infections

  2003cites this paper
• Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections

  2003cites this paper
• Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults

  2003cites this paper